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Review Article
Prognostication of uveal melanoma is simple and highly predictive using The
Cancer Genome Atlas (TCGA) classification: A review
Carol L Shields, Lauren A Dalvin, Pornpattana Vichitvejpaisal, Mehdi Mazloumi, Arupa Ganguly1,
Jerry A Shields
Purpose: The cancer genome atlas (TCGA) is a comprehensive project supported by the National
Cancer Institute (NCI) in the United States to explore molecular alterations in cancer, including uveal
melanoma (UM). This led to TCGA classification for UM. In this report, we review the American Joint
Committee on Cancer (AJCC) classification and TCGA classification for UM from the NCI’s Center
for Cancer Genomics (NCI CCG) (based on enucleation specimens [n = 80 eyes]) and from Wills Eye
Hospital (WEH) (based on fine needle aspiration biopsy [FNAB] specimens [n = 658 eyes]). We then compare
accuracy and predictability of AJCC versus (vs.) TCGA. Methods: Review of published reports on AJCC and
TCGA classification for UM was performed. Outcomes based on AJCC 7th and 8th editions were assessed.
For TCGA, UM was classified based on chromosomes 3 and 8 findings including disomy 3 (D3), monosomy
3 (M3), disomy 8 (D8), 8q gain (8qG), or 8q gain multiple (8qGm) and combined into four classes including
Class A (D3/D8), Class B (D3/8qG), Class C (M3/8qG), and Class D (M3/8qGm). Outcomes of metastasis
and death were explored and a comparison (AJCC vs. TCGA) was performed. Results: In the NCI CCG
study, there were 80 eyes with UM sampled by enucleation (n = 77), resection (n = 2), or orbitotomy (n = 1)
and analysis revealed four distinct genetic classes. Metastasis and death outcomes were subsequently
evaluated per class in the WEH study. The WEH study reviewed 658 eyes with UM, sampled by FNAB,
and found Class A (n = 342, 52%), B (n = 91, 14%), C (n = 118, 18%), and D (n = 107, 16%). Comparison by
increasing class (A vs. B vs. C vs. D) revealed older mean patient age (P < 0.001), worse entering visual
acuity (P < 0.001), greater distance from the optic disc (P < 0.001), larger tumor diameter (P < 0.001), and
greater tumor thickness (P < 0.001). Regarding outcomes, more advanced TCGA class demonstrated
increased 5‑year risk for metastasis (4% vs. 20% vs. 33% vs. 63%, P < 0.001) with corresponding increasing
hazard ratio (HR) (1.0 vs. 4.1, 10.1, 30.0, P = 0.01 for B vs. A and P < 0.001 for C vs. A and D vs. A) as well
as increased 5‑year estimated risk for death (1% vs. 0% vs. 9% vs. 23%, P < 0.001) with corresponding
increasing HR (1 vs. NA vs. 3.1 vs. 13.7, P = 0.11 for C vs. A and P < 0.001 for D vs. A). Comparison of
AJCC to TCGA classification revealed TCGA was superior in prediction of metastasis and death from UM.
Conclusion: TCGA classification for UM is simple, accurate, and highly predictive of melanoma‑related
metastasis and death, more so than the AJCC classification.
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Prognostication is a valuable tool in the management of uveal
melanoma (UM) in terms of understanding cancer biology,
knowing the rate and impact of metastatic disease, providing
management options for patients, and consideration of new
therapeutic alternatives in clinical trials. There are several
prognostic parameters that have been explored in the past
including tumor location, basal dimension and thickness,
histopathologic cell type, vascular mimicry patterns, infiltrating
lymphocytes, and others. More recently, tumor categorization
by the American Joint Committee on Cancer (AJCC) staging and
by genetic analysis or gene expression profiling have become of
utmost importance. Herein, we will review UM classification
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using AJCC and genetic testing, and will explore the new
nationally sponsored, multicenter effort of TCGA project.

Prognostication of UM by American Joint
Committee on Cancer (AJCC)
The AJCC staging manual is designed to provide a detailed
classification for numerous solid cancers, including UM.[1]
The intent of this classification is to allow clinicians to assess
tumor extent with a uniform language and ultimately improve
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understanding and prognostication of cancer. This classification
scheme is based on tumor (T), node (N), and metastasis (M),
and is sometimes referred to as the “TNM classification”.
The tumor is graded according to size category based on a
combination of basal diameter and thickness and labeled as
T1, T2, T3, and T4 with increasing category. Subclassification
of each T category is judged by (a) the absence of ciliary
body (CB) involvement and extraocular extension, (b) the
presence of CB involvement, (c) the presence of extraocular
extension ≤5 mm, (d) the presence of both CB involvement
and extraocular extension ≤5 mm, and (e) any tumor size
category with extraocular extension >5 mm diameter.[2] The
node and metastasis are graded as present or absent with
tumor invasion and metastasis additionally is graded by
nodule size of (a) ≤3 cm, (b) 3.1–8.0 cm, and (c) ≥8.1 cm. This is
further refined into prognostic staging based on the T, N, and
M findings. The AJCC classification includes histopathologic
grade (G) as (1) spindle melanoma, (2) mixed melanoma,
and (3) epithelioid melanoma.
Several studies have explored the AJCC classification
regarding prognostic capability for UM. Most studies[3‑5]
have focused on AJCC 7th edition as the 8th edition was only
recently released. Shields et al. released two reports on a single
center AJCC classification 7th edition in 7731 patients with
posterior UM based on T category and, subsequently, based
on anatomic stage.[3,4] Regarding T category, they found UM
was categorized as T1 in 3557 (46%), T2 in 2082 (27%), T3 in
1599 (21%), and T4 in 493 (6%).[3] There were clinical features
that increased per T category (T1, T2, T3, T4) including patient
age (57, 58, 58, 61 years, P < 0.001), tumor base (8, 12, 15, 20 mm,
P < 0.001), tumor thickness (3.5, 5.2, 8.9, 11.4 mm, P < 0.001),
mushroom configuration (8%, 20%, 38%, 39%, P < 0.001),
associated subretinal fluid (64%, 80%, 82%, 83%, P < 0.001),
Bruch’s membrane rupture (9%, 24%, 40%, 40%, P < 0.001), and
extraocular extension (1%, <1%, 4%, 12%, P < 0.001).
These authors found that T category was strongly predictive
of metastatic disease. Using Kaplan–Meier estimates of
metastasis (at 5, 10, 20 years) following therapy they found
increasing rate of metástasis per category, including category
T1 (8%, 15%, 25%), T2 (14%, 25%, 40%), T3 (31%, 49%, 62%), and
T4 (51%, 63%, 69%) (P < 0.001 at all time points).[3] Compared to
category T1, the HR for metastasis for T2 was 1.8, T3 was 4.5,
and T4 was 8.2. Similar increasing risk was noted for death by
Kaplan–Meier analysis.
Subsequent analysis on this cohort of 7731 patients with
posterior UM was performed based on anatomic stage,
revealing stage I in 2767 (36%), stage II in 3735 (48%), stage
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III in 1220 (16%), and stage IV in 9 (<1%).[4] By specific tumor
stage (I, II, III, IV), some clinical features demonstrated
significant increase per stage, including age at diagnosis (57, 58,
60, 60 years, P < 0.001), tumor base (8, 12, 17, 17 mm, P < 0.001),
tumor thickness (2.9, 6.0, 10.1, 10.2 mm, P < 0.001), distance to
optic disc (3, 5, 5, 5 mm, P < 0.001), distance to foveola (3, 5,
5, 5 mm, P < 0.001), mushroom configuration (6%, 24%, 34%,
33%, P < 0.001), and extraocular extension (0%, 1%, 11%, 22%,
P < 0.001). The tumor stage was highly predictive of risk for
metastasis (at 5, 10 years), including stage I (5%, 12%), stage
II (17%, 29%), stage III (44%, 61%), and stage IV (100% by
1 year)[4] [Table 1]. They concluded that the rate of metastasis
was 3.1 times greater for stage II, 9.3 times greater for stage III,
and greater yet for stage IV, compared to stage I.
The multicenter AJCC Ophthalmic Oncology Task Force
provided a similar analysis on the predictive value of the AJCC
classification 7th edition in 2015.[5] They investigated 3127 patients
with posterior UM and found categories of T1 (35%), T2 (35%),
T3 (24%), and T4 (6%). They evaluated the Kaplan–Meier
metastasis‑free estimates (5, 10 years) and result revealed
T1 (97%, 94%), T2 (85%, 80%), T3 (77%, 68%), and T4 (61%, 5‑year
only)). Increasing category was associated with increasing risk
for metastasis (P < 0.001).[5] They also explored AJCC anatomic
stage and found the Kaplan–Meier metastasis‑free point
(5, 10 years) revealed stage 1 (97%, 94%), stage IIA (89%, 84%),
stage IIB (79%, 70%), stage IIIA (67%, 60%), stage IIIB (50%,
50%), and stage IIIC (25%, 5‑year only). They indicated that
this multicenter, internet‑based data sharing was able to study
a heterogeneous patient population from around the world and
demonstrate the facility of the AJCC 7th edition classification.[5]

Prognostication of UM by Genetic Analysis
There have been several centers interested in prognostication
of UM by genetic alterations.[6‑15] Genetic testing has become
the standard of care for modern UM management. Most ocular
oncologists employ fine needle aspiration biopsy (FNAB) to
sample melanoma for genetic profile immediately preceding the
time of plaque radiotherapy or proton beam radiotherapy. The
sample is sent for a DNA‑based or RNA‑based evaluation. Our
team prefers DNA‑based evaluation as it is highly predictive
of prognosis and is quite affordable for the patient. Once the
genetic profile is received, then stratification of the patient,
based on genetic results, into low or high risk for metastatic
disease is performed and patient management is adjusted. This
affects surveillance decisions regarding frequency of systemic
monitoring, enrollment into adjuvant systemic therapy for
reduction of metastatic potential and consideration of patient
psychologic concerns.

Table 1: American Joint Committee on Cancer (AJCC) classification (anatomic stage) can predict uveal melanoma‑related
metastasis in 7731 patients
AJCC

Metastasis
@ 1 year

@ 3 years

@ 5 years

@ 10 years

@ 15 years

@ 20 years

Stage I

<1%

2%

5%

12%

15%

20%

Stage II

2%

10%

17%

29%

36%

44%

Stage III
Stage IV

6%
100%

26%
‑

44%
‑

61%
‑

73%
‑

73%
‑

Data from Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA, et al. American Joint Committee on Cancer classification of uveal
melanoma (anatomic stage) predicts prognosis in 7731 patients. The 2013 Zimmerman Lecture. Ophthalmology 2015;122:1180‑6
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In 2017, Shields et al. provided a large cohort assessment
on FNAB genetic testing in 1059 consecutive patients with
UM, with specific focus on abnormalities in chromosomes
3, 6, and 8.[10] By combination of cytogenetic abnormalities,
Kaplan–Meier risk estimates (3, 5 years) for melanoma‑related
metastasis for 3, 6, and 8 disomy (1%, 4%) were low compared
with higher‑risk combinations of monosomy 3, 6p gain, and
8q gain (29%, 29%), monosomy 3, disomy 6, 8q gain, and 8p
gain (14%, (not evaluable)), monosomy 3, disomy 6, and 8q
gain (27%, 39%), and monosomy 3, disomy 6, 8q gain, and 8p
loss (28%, (not evaluable)) [Table 2].[10] Later, they correlated
melanoma cytogenetics with clinical features and found those
with any mutation in chromosomes 3, 6, or 8 (vs. no mutation)
showed significant differences in mean age (58 vs. 55 years,
P = 0.02), ocular melanocytosis (5% vs. 1%, P = 0.03), mean
visual acuity (VA) (20/50 vs. 20/30, P = 0.01), poor VA ≤20/200)
(15% vs. 9%, P = 0.04), ciliary body location (11% vs. 5%, P < 0.001),
increased mean distance to optic disc (5.0 vs. 3.3 mm, P < 0.001),
and foveola (4.7 vs. 3.1 mm, P < 0.001), and increased mean basal
diameter (12.6 vs. 9.8 mm, P < 0.001) and thickness (5.9 vs. 3.8 mm,
P < 0.001).[11] Damato and Coupland emphasized the importance
of prognostication with combination of tumor basal dimension
with genetic tumor type and melanoma cell type.[9] Since then,
others have corroborated the importance of tumor size with gene
expression profiling and other genetic factors.[12,13]
In 2017, Dogrusoz et al. reported that the AJCC staging can
be improved by adding chromosomal status.[15] They studied
522 patients treated for UM and found stage I (17%), stage
II (59%), stage III (23%), and stage IV (1%). They noted 5‑year
cumulative rate of melanoma‑related death differed from those
with AJCC stage I and no monosomy 3 or 8q gain (0%) to those
with AJCC stage III and monosomy 3 and 8 q gain (73%) [Table 3].
By multivariable Cox regression analysis, the largest HRs
identified AJCC stage III tumors (HR 8.8 P < 0.001) and tumors
with monosomy 3 plus 8q gain (HR 7.95, P < 0.001).

TCGA Project
TCGA is a project that was initiated in 2005 to comprehensively
explore genetic mutations found in human cancer.[16‑18] TCGA
was funded by the United States government and directed by
the National Cancer Institute’s Center for Cancer Genomics
and the National Human Genome Research Institute. The first
three projects concerned glioblastoma multiforme, lung cancer,

and ovarian cancer. In 2009, the project expanded to include 33
different solid cancers, including ten rare cancers.[17] Evaluation
techniques comprised gene expression profiling, copy
number variation profiling, SNP genotyping, genome‑wide
DNA methylation profiling, microRNA profiling, and exon
sequencing. Later, whole exome and whole transcriptome
sequencing were performed in all cases.

TCGA from the National Cancer Institute’s
Center for Cancer Genomics (NIH CCG)
for Uveal Melanoma (Based on Enucleation
Specimens in 80 Cases)
TCGA researchers from the National Cancer Institute’s
Center for Cancer Genomics (NIH CCG) studied 80 cases
with histopathologically proven UM, confirmed following
enucleation (n = 77), resection (n = 2), or orbitotomy (n = 1).[19] This
research confirmed previous data documenting the importance
of chromosome 3 monosomy (M3) and chromosome 3 disomy
(D3).[6‑11] Furthermore, it was noted that most M3 tumors
demonstrated BAP1 alteration and BAP1 mutated tumors
revealed unique global DNA methylation profile. Importantly,
these researchers documented some differences between
uveal and cutaneous melanoma, noting that UM has lower
somatic mutational density, no ultraviolet radiation mutational
signature, and a unique set of mutated genes, compared to
cutaneous melanoma.[19]
TCGA used a comprehensive multiplatform assessment
of this cohort of UM and found four molecularly distinct
and clinically relevant subgroups based on alterations in
chromosomes 3 and 8 (disomy 3 (D3), monosomy 3 (M3),
disomy 8 (D8), 8q gain (8qG), or 8q gain multiple (8qGm)). Jager
et al. recognized and labeled these 4 classes as Class A (D3/D8),
Class B (D3/8qG), Class C (M3/8qG), and Class D (M3/8qGm).[20]
Based on estimation, the best prognosis was with classes A and
B and worst with classes C and D tumors.[20]

TCGA Validation from Wills Eye Hospital
(WEH) (Based on Fine Needle Aspiration
Biopsy [FNAB] Specimens in 658 Cases)
In 2019, Vichitvejpaisal et al. analyzed 658 eyes with UM at
WEH sampled by FNAB for genetic analysis over a 10‑year

Table 2: Uveal melanoma prognosis based on cytogenetic testing of three chromosomes in 534 cases
Chromosomal abnormality
3

6q

0
0
0

Kaplan-Meier estimate for metastasis

P

6p

8q

8p

@1 year

@3 years

@5 years

0

0

0

0

1%

1%

4%

ns

0

Gain

0

0

3%

3%

15%

ns

Loss

Gain

Gain

0

0%

0%

33%

ns

Monosomy

0

0

0

0

0%

8%

8%

ns

Monosomy

0

0

Gain

0

8%

27%

39%

P<0.001

Monosomy

0

0

Gain

Loss

3%

28%

NE

P<0.001

Monosomy

Loss

0

Gain

Loss

20

60

NE

P<0.001

Monosomy
Monosomy

Loss
Loss

Gain
Gain

Gain
Gain

0
Loss

50
25

50
NE

NE
NE

P<0.001
P<0.001

0=normal, NE=not evaluable. Data adapted from [10]Shields CL, Say EAT, Hasanreisoglu M, Saktanasate J, Lawson BM, Landy JE, et al. Personalized prognosis
of uveal melanoma based on cytogenetic profile in 1059 patients over an 8‑year period: The 2017 Harry S. Gradle Lecture. Ophthalmology 2017;124:1523‑31
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period.[21] They subsequently classified the eyes based on TCGA
and found the following distribution: class A (n = 342, 52%),
B (n = 91, 14%), C (n = 118, 18%), and D (n = 107, 16%) [Table 4].
Based on tumor class, there were differences in demographics
and clinical features. By demographics, TCGA class (A vs.
B vs. C vs. D) showed more advanced tumor class with older
age (56 vs. 53 vs. 60 vs. 63 years, P < 0.001) and poorer visual
acuity (Snellen visual acuity 20/20‑20/50 in 81% vs. 67% vs. 71%
vs. 66%, P < 0.001).[21] There was no difference in sex (P = 0.38),
Caucasian race (P = 0.28), or affected eye (P = 0.62). By clinical
features, more advanced tumor class was located more
anteriorly in the ciliary body (4% vs. 8% vs. 16% vs. 11%,
P < 0.001), with greater distance from the optic disc (3.5 vs.
4.9 vs. 5.7 vs. 5.3 mm, P < 0.001) and foveola (3.2 vs. 4.3 vs. 5.3 vs.
5.1 mm, P < 0.001) and with larger tumor diameter (10.3 vs.
Table 3: Combination of American Joint Committee on
Cancer (AJCC) classification and tumor genetics can
improve prognostication of uveal melanoma metastatic
risk
AJCC
Stage

5‑year cumulative rate of melanoma‑related
death (%)
Chromosome status
No monosomy 3
and no 8q gain

Monosomy 3
or 8q gain

Monosomy 3
and 8q gain

I

0%

0%

25%

II
III

11%
9%

17%
32%

50%
73%

Data adapted from [15]Dogrusoz M, Bagger M, van Duinen SG, Kroes WG,
Ruivenkamp CA, Böhringer S, et al. The prognostic value of AJCC staging
in uveal melanoma is enhanced by adding chromosome 3 and 8q status.
Invest Ophthalmol Vis Sci 2017;58:833‑42

Volume 67 Issue 12

12.9 vs. 13.9 vs. 15.3 mm, P < 0.001) and thickness (4.3 vs. 6.1 vs.
6.6 vs. 7.5 mm, P < 0.001).[21]
This report demonstrated that patient outcomes paralleled
increasing tumor class.[21] By comparison of TCGA class (A
vs. B vs. C vs. D), there was significant increase in the 5‑year
cumulative percentage of distant metastasis (4% vs. 20% vs.
33% vs. 63%, P < 0.001), the 5‑year cumulative percentage of
liver metastasis (2% vs. 14% vs. 32% vs. 61%, P < 0.001), and
the 5‑year cumulative percentage of death (1% vs 0% vs. 9% vs.
23%, P < 0.001) as well as corresponding HRs for metastasis and
death [Table 4].[21] These authors concluded that categorizing
UM by TCGA classification can reliably predict risk for
melanoma‑related metastasis and death.[21] This classification
scheme could prove useful for future studies targeted at
treatment of high‑risk tumor.

Comparison of TCGA versus AJCC
Classification
In 2019, Mazloumi et al. compared the AJCC 8 th edition
with TCGA for simplicity, accuracy, and robustness in
prediction of UM metastasis.[22] They reviewed the clinical
features and genetic results of 643 patients that were
sampled by FNAB preceding plaque radiotherapy. Using
univariate Cox‑regression analysis, TCGA classification
demonstrated greater prognostic acumen for prediction of
melanoma‑related metastasis (TCGA vs. AJCC 4 T categories
vs. AJCC 17 T subcategories vs. AJCC 4 stages) (Wald:
94.8 vs. 67.5 vs. 74.3 vs. 67.0, P < 0.001 for all). By multivariate
model, TCGA classification continued to demonstrate
greater prognostic value (TCGA vs. AJCC) for metastatic
disease (Wald: 61.5 vs. 35.5, P < 0.001 for both). The authors
indicated that TCGA is superior to AJCC for prediction of
UM‑related metastasis.[22]

Table 4: Genetic features and outcome of uveal melanoma in 658 patients based on The Cancer Genome Atlas (TCGA)
Classification of A, B, C, & D
The Cancer Genome Atlas (TCGA) Class
D

P

Monosomy 3

Monosomy 3

NA

8q gain

8q gains (multiple)

NA

Late metastases

Unfavorable

Unfavorable

NA

342 (52%)

91 (14%)

118 (18%)

107 (16%)

4%

20%

33%

63%

P<0.001

A

B

C

Chromosome 3

Disomy 3

Disomy 3

Chromosome 8

Disomy 8q

8q gain

Favorable

Mutational profile

Prognosis per TCGA[19,20]
Estimated outcome
Prognosis per Wills Eye Hospital series[21] (n=658)
Number of patients (%)
5‑year cumulative rate for distant metastasis
5‑year odds ratio for distant metastasis*

1.0

3.5

11.4

26.4

P<0.001

5‑year cumulative rate for liver metastasis

2%

14%

32%

61%

P<0.001

5‑year odds ratio for liver metastasis*

1.0

5.9

18.4

42.9

P<0.001

5‑year cumulative rate for death
5‑year odds ratio for death*

1%
1.0

0%
NA

9%
2.1

23%
5.9

P<0.001
P=0.09

TCGA ‑ The Cancer Genome Atlas, NA – not applicable. [19]Data from Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis
identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 2017;32:204‑20 e215 and Jager MJ, Brouwer NJ, Esmaeli B. The cancer genome
atlas project: An integrated molecular view of uveal melanoma. Ophthalmology 2018;125:1139‑42. [20]From Jager MJ, Brouwer NJ, Esmaeli B. The cancer
genome atlas project: An integrated molecular view of uveal melanoma. Ophthalmology 2018;125:1139‑42. [21]Data from Vichitvejpaisal P, Dalvin LA, Mazloumi
M, Ewens KG, Ganguly A, Shields CL, et al. Genetic analysis of uveal melanoma in 658 patients using The Cancer Genome Atlas (TCGA) classification of uveal
melanoma as A, B, C & D. Ophthalmology 2019;126:1445‑53. *Compared to Class A
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Conclusion
Prognostication of UM has gradually evolved over the past
decades from tumor clinical and histopathologic features
to more recently AJCC classification, cytogenetic and gene
expression profiling, to now TCGA classification. The
accuracy, simplicity, and superior prognostication of TCGA
allows for better understanding of UM behavior with hope
for improvement in adjuvant therapies to reduce the risk of
metastasis in clinical care at a personalized level.
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